Circular RNA_0001946 is insufficiently expressed in tumor tissues, while its higher expression correlates with less lymph node metastasis, lower TNM stage, and improved prognosis in NSCLC patients

Minghua Zhang\(^1\) | Fangjing Wen\(^1\) | Ke Zhao\(^2\)

\(^1\)Department of Respiratory Disease, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
\(^2\)Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

**Correspondence**
Ke Zhao, Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, 26 Shengli Street, Jiang’an District, Wuhan 430014, China.
Email: ketu96780861@126.com

**Abstract**

**Objective:** Circular RNA_0001946 (circ_0001946) inhibits tumor progression but promotes chemosensitivity in non-small-cell lung cancer (NSCLC); however, its correlation with tumor features and prognosis in NSCLC patients is still unclear; therefore, this study aimed to investigate these issues.

**Methods:** A total of 284 NSCLC patients were retrospectively analyzed. Circ_0001946 expression in tumor (n = 284) and adjacent (n = 125) tissues was detected by the reverse transcription-quantitative polymerase chain reaction. Meanwhile, patients’ clinical characteristics, recurrence, and survival data were extracted from the electrical database.

**Results:** Circ_0001946 expression in adjacent tissues was over 3-folds as that in tumor tissues (\(P < .001\)). Meanwhile, higher tumor circ_0001946 expression was correlated with less lymph node metastasis (\(P < .001\)) and decreased TNM stage (\(P = .001\)), but did not correlate with other clinicopathological features. Moreover, higher tumor circ_0001946 expression was associated with prolonged disease-free survival (DFS) (\(P < .001\)) and overall survival (OS) (\(P < .001\)), respectively. Subgroup analyses revealed that higher tumor circ_0001946 was correlated with improved DFS in patients with TNM stage I, II, or III, respectively (all \(P < .05\)), while only correlated with prolonged OS in patients with TNM stage III (\(P = .037\)), but not in patients with TNM stage I or II. Further multivariate Cox's proportional hazard regression analyses suggested that higher tumor circ_0001946 expression could independently predict improved DFS (\(P < .001\), hazard ratio (HR) = 0.719) and OS (\(P < .001\), HR = 0.746), respectively.

**Conclusion:** Circ_0001946 is insufficiently expressed in tumor tissues, whereas its higher expression correlates with less lymph node metastasis, reduced TNM stage, and improved prognosis in NSCLC patients.
1 | INTRODUCTION

Non-small-cell lung cancer (NSCLC) is a global health issue that affects over 2.1 million people and causes above 1.7 million deaths annually.\(^2\)\(^-\)\(^4\) Thanks to the improvement in early detection techniques and treatment strategies for NSCLC, the mortality of NSCLC patients has decreased slightly in western countries in recent years.\(^2\)\(^-\)\(^4\) However, partly due to the increase in smoking population and air pollution in the past decades, the incidence of NSCLC is still rising in China, thus making NSCLC a major public health concern.\(^5\)\(^,\)\(^6\) One potential strategy to ameliorate this situation might be searching for novel prognostic biomarkers in NSCLC patients to improve the management toward them.\(^7\)\(^,\)\(^8\)

In recent years, circular RNAs (circRNAs) have received vast interest from the researchers, and numerous studies have revealed that circRNAs could regulate the initiation and progression of various diseases, including cancer.\(^9\)\(^,\)\(^10\) CircRNA_0001946 (circ_0001946), as a newly discovered circRNA, has been reported to participate in the progression of several cancers. For instance, in glioblastoma, circ_0001946 suppresses proliferation, migration, and invasion both in vitro and in vivo\(^11\); in bladder cancer, it also represses cell proliferation, migration, and invasion,\(^12\) while, in colorectal cancer, circ_0001946 promotes cell proliferation and epithelial-mesenchymal transition.\(^13\) Moreover, in NSCLC, it is reported that circ_0001946 reduces cancer cell proliferation, migration, and invasion, but promotes cancer cell chemosensitivity to cisplatin.\(^14\) Based on the effect of circ_0001946 on tumor cell progression and chemosensitivity in cancers including NSCLC, we hypothesized that circ_0001946 might be a potential clinical biomarker in NSCLC, whereas relevant information is unclear.

In this retrospective study, we enrolled 284 surgical NSCLC patients, aimed to investigate circ_0001946 relative expression and its correlation with tumor characteristics as well as prognosis in NSCLC.

2 | MATERIALS AND METHODS

2.1 | Patients

This study retrospectively reviewed 284 NSCLC patients who received resection in our hospital from January 2015 to December 2019. All patients were confirmed as NSCLC by pathological evaluation. The adult patients who had well-preserved freshly frozen tumor tissues and complete clinical/follow-up data were included in this study. In addition, the patients who received neoadjuvant therapy or history of complicated with other cancers were excluded. This study was approved by the Ethics Committee of our hospital. All patients or their family members provided written informed consents.

2.2 | Data collection

The clinical data were collected from patients’ electronic medical records, which included age, gender, history of smoke, history of drink, hypertension, hyperlipidemia, diabetes, differentiation, tumor size, lymph node metastasis, TNM stage, and carcinoembryonic antigen (CEA) level. The follow-up data were collected from the follow-up record, and the last follow-up date was January 31, 2020. The disease status and survival status were obtained from the follow-up data, and disease-free survival (DFS) and overall survival (OS) were calculated. DFS was defined as the duration from surgery to the date of disease relapse or death. OS was defined as the duration from surgery to the date of death.

2.3 | Circ_0001946 detection

Freshly frozen tumor tissues of 284 patients were acquired from the storeroom of the Pathology Department. Besides, 125 patients among 284 patients also had paired freshly frozen adjacent tissues, and the 125 adjacent tissues were collected as well. The expression of circ_0001946 in tumor tissues and adjacent tissues was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in accordance with the method described in a previous study with some modification.\(^14\) In brief, TRIzol® Reagent (Thermo Fisher Scientific) was used for total RNA extraction. Next, for circRNA detection, RNase R (Epicentre) was used to digest linear RNA, while, for GAPDH RNA detection, linear RNA digestion was not conducted. Subsequently, PrimeScript™ RT reagent Kit (Takara) was applied for reverse transcription, and TB Green™ Fast qPCR Mix (Takara) was used for qPCR. All reagents or kits were used under the manufacturers’ instructions. GAPDH was used as the internal reference, and circ_0001946 relative expression was calculated by the 2\(^{-}\Delta\Delta Ct\) formula.\(^14\) The primers were designed according to the previous study.\(^14\) Circ_0001946 forward primer: 5′-TTCAGGTGCTGATCTCTGAC-3′, reverse primer: 5′-TGGAGAACCCGGAGTGGTG-3′; GAPDH forward primer: 5′-GA CACAGTGCCATGCATCAC-3′, reverse primer: 5′-ACGGCTGCTTC ACCACCTT-3′.

2.4 | Statistical analysis

Statistical analysis was performed with the use of SPSS 24.0 (IBM). The figures were plotted using GraphPad Prism 8.01 (GraphPad Software Inc.). The Kolmogorov-Smirnov test was used for the normality test of continuous variables. Normally distributed continuous variables were displayed as mean ± standard deviation (SD), and
unknown distributed continuous variables were expressed as median with interquartile range (IQR). Categorical variables were presented as numbers and percentages. Wilcoxon rank-sum test was used to compare circ_0001946 expression between adjacent tissues and tumor tissues. In order to analyze the correlation of tumor circ_0001946 expression with clinical characteristics and prognosis, the expression of circ_0001946 in tumor tissue was further categorized as Q1 (quartile 1%-25%), Q2 (quartile 25%-50%), Q3 (quartile 50%-75%), and Q4 (quartile 75%-100%). Linear-by-linear association test or Spearman’s rank correlation test was used to analyze the correlation of circ_0001946 with clinical characteristics. Kaplan-Meier curve was plotted, and the log-rank test was used for comparing the difference in DFS and OS among groups. Forward stepwise multivariate Cox’s proportional hazard regression model was used to analyze the factors correlated with DFS and OS. P value < .05 was considered as significant.

3 | RESULTS

3.1 | Description of patients’ characteristics

A total of 457 NSCLC patients who received resection were screened, and 85 of them were excluded (including 46 patients who were unable to contact and 39 patients who refused to participate). Then, the remaining 372 patients were reviewed; then, 88 of them were excluded (including 42 patients who received neoadjuvant therapy, 26 patients who had no eligible tumor tissue, and 20 patients who had no complete clinical or follow-up data). Finally, 284 eligible NSCLC patients were analyzed (Figure 1). Patients’ characteristics were shown in Table 1. Briefly, the mean age of patients was 63.0 ± 11.3 years, 56 (19.7%) patients were female, and 228 (80.3%) patients were male. With regard to tumor differentiation, 53 (18.7%) patients were well differentiated, 166 (58.5%) patients were moderately differentiated, and 65 (22.9%) patients were poorly differentiated. Meanwhile, the mean tumor size was 5.4 ± 2.1 cm, 163 (57.4%) patients had tumor size less than or equal to 5.0 cm, and 121 (42.6%) patients had tumor size greater than 5.0 cm. Besides, 190 (66.9%) patients did not have lymph node metastasis, while 94 (33.1%) patients had lymph node metastasis. As to TNM stage, 89 (31.3%) patients were of stage I, 103 (36.3%) patients were of stage II, and 92 (32.4%) patients were of stage III. Moreover, the median level of CEA was 5.7 (2.5-26.8) ng/mL, 134 (47.2%) patients were of normal CEA level, and 150 (52.8%) patients were of abnormal CEA level.

3.2 | Circ_0001946 expression

RT-qPCR analysis showed that the median level of circ_0001946 in adjacent tissues (median level: 1.000 (0.750-1.294)) was over 3-folds as that in tumor tissues (median level: 0.291 (0.194-0.436) in NSCLC patients (P < .001) (Figure 2).

3.3 | Correlation of tumor circ_0001946 expression with clinical characteristics

Subsequently, correlation analysis revealed that tumor circ_0001946 expression was negatively correlated with lymph node metastasis (P < .001) and TNM stage (P = .001). However, no correlation was observed in tumor circ_0001946 expression with age (P = .446), gender (P = .187), history of smoke (P = .670), history of drink (P = .075), hypertension (P = .293), hyperlipidemia (P = 1.000), diabetes (P = .941), tumor differentiation (P = .185), tumor size (P = .097), or CEA level (P = .089) in NSCLC patients (Table 2).

3.4 | Correlation of tumor circ_0001946 expression with patients’ prognosis

Moreover, patients’ recurrence and survival status were acquired, and their DFS and OS were calculated. Data showed that higher tumor circ_0001946 expression was associated with improved DFS (P < .001) (Figure 3A) and OS (P < .001) in NSCLC patients (Figure 3B).

3.5 | Subgroup analysis

In addition, the correlation of tumor circ_0001946 expression with prognosis in patients with different TNM stages was analyzed. As to DFS, data revealed that higher TNM stage was associated with worse DFS (P < .001) (Figure 4A); meanwhile, higher tumor circ_0001946 expression was associated with prolonged DFS in patients with TNM stage I (P = .033) (Figure 4B), TNM stage II (P = .015) (Figure 4C), and TNM stage III (P = .028), respectively (Figure 4D).
With regard to OS, higher TNM stage was also associated with worse OS ($P < .001$) (Figure 5A); however, higher tumor circ_0001946 was only associated with increased OS in patients with TNM stage III ($P = .037$) (Figure 5D), but not in patients with TNM stage I ($P = .051$) (Figure 5B) or TNM stage II ($P = .168$) (Figure 5C). These data indicated that circ_0001946 might be a stronger prognostic factor in NSCLC patients with TNM stage III.

### 3.6 Independent factors for patients' prognosis

Further multivariate Cox's proportional hazard regression analysis revealed that higher tumor circ_0001946 expression ($P < .001$, HR = 0.719), age > 60 years ($P = .033$, HR = 0.714), and radiotherapy ($P = .016$, HR = 0.601) were independently correlated with improved DFS, while hyperlipidemia ($P = .020$, HR = 1.487), lymph node metastasis ($P = .031$, HR = 1.479), and higher TNM stage ($P = .001$, HR = 1.517) were independently correlated with worse DFS (Table 3). Besides, higher tumor circ_0001946 expression was also independently correlated with improved OS ($P < .001$, HR = 0.746), but hyperlipidemia ($P = .002$, HR = 1.874), history of drink ($P = .022$, HR = 1.530), poor tumor differentiation ($P = .007$, HR = 1.496), and lymph node metastasis ($P < .001$, HR = 2.945) were independently correlated with reduced OS (Table 4).

### 4 DISCUSSION

CircRNAs have aroused the interest of researches during the past few years. As a newly discovered circRNA, circ_0001946 presents regulation on several tumors. For example, in glioblastoma, circ_0001946 overexpression suppresses cell proliferation, migration, and invasion through targeting microRNA (miR)-671-5p, and in vivo experiments further verify these findings. Meanwhile, in colorectal cancer, circ_0001946 also

---

**TABLE 1** Patients’ characteristics

| Items                        | NSCLC patients (n = 284) |
|------------------------------|--------------------------|
| Age (y), mean ± SD           | 63.0 ± 11.3              |
| ≤60 y, no. (%)               | 110 (38.7)               |
| >60 y, no. (%)               | 174 (61.3)               |
| Gender, No. (%)              |                          |
| Female                       | 56 (19.7)                |
| Male                         | 228 (80.3)               |
| History of smoke, No. (%)    |                          |
| No                           | 128 (45.1)               |
| Yes                          | 156 (54.9)               |
| History of drink, No. (%)    |                          |
| No                           | 169 (59.5)               |
| Yes                          | 115 (40.5)               |
| Hypertension, No. (%)        |                          |
| No                           | 183 (64.4)               |
| Yes                          | 101 (35.6)               |
| Hyperlipidemia, No. (%)      |                          |
| No                           | 192 (67.6)               |
| Yes                          | 92 (32.4)                |
| Diabetes, No. (%)            |                          |
| No                           | 241 (84.9)               |
| Yes                          | 43 (15.1)                |
| Tumor differentiation, No. (%)|                      |
| Well                         | 53 (18.7)                |
| Moderate                     | 166 (58.5)               |
| Poor                         | 65 (22.9)                |
| Tumor size (cm), mean ± SD   | 5.4 ± 2.1                |
| ≤5.0 cm, no. (%)             | 163 (57.4)               |
| >5.0 cm, no. (%)             | 121 (42.6)               |
| Lymph node metastasis, No. (%)|                      |
| No                           | 190 (66.9)               |
| Yes                          | 94 (33.1)                |
| TNM stage, No. (%)           |                          |
| I                            | 89 (31.3)                |
| II                           | 103 (36.3)               |
| III                          | 92 (32.4)                |
| CEA (ng/mL), median (IQR)    | 5.7 (2.5–26.8)           |
| Normal (≤5 ng/mL), no. (%)   | 134 (47.2)               |
| Abnormal (>5 ng/mL), no. (%) | 150 (52.8)               |
| Adjuvant therapy             |                          |
| No adjuvant therapy          | 61 (21.5)                |
| CT                           | 136 (47.9)               |
| RT                           | 60 (21.1)                |
| CCRT                         | 71 (25.0)                |

Abbreviations: CCRT, concurrent chemoradiotherapy; CEA, carcinoembryonic antigen; CT, chemotherapy; IQR, interquartile range; NSCLC, non-small-cell lung cancer; RT, radiotherapy; SD, standard deviation.
regulates cell proliferation, migration, and invasion through modifying the epithelial-mesenchymal transition (EMT) pathway. In addition, in NSCLC, circ_0001946 knockdown promotes cell proliferation, migration, invasion, and the sensitivity to cisplatin through modulating the nucleotide excision repair (NER) pathway. Therefore, circ_0001946 not only critically regulates the progression, but also plays an important role in the chemosensitivity of several tumors, including NSCLC.

### TABLE 2 Correlation analysis between circ_0001946 and clinical characteristics

| Items                        | Circ_0001946 expression* |  |  |  | P value |
|------------------------------|---------------------------|---|---|---|---------|
|                             | Q1 (0%-25%, n = 71)       | Q2 (25%-50%, n = 71) | Q3 (50%-75%, n = 71) | Q4 (75%-100%, n = 71) |
| Age, No. (%)                 |                           |   |   |   |         |
| ≤60 y                        | 28 (39.4)                 | 30 (42.3) | 28 (39.4) | 24 (33.8) | .446    |
| >60 y                        | 43 (60.6)                 | 41 (57.7) | 43 (60.6) | 47 (66.2) | .187    |
| Gender, No. (%)              |                           |   |   |   |         |
| Female                       | 10 (14.1)                 | 19 (26.8) | 11 (15.5) | 16 (22.5) | .670    |
| Male                         | 61 (85.9)                 | 52 (73.2) | 60 (84.5) | 55 (77.5) |         |
| History of smoke, No. (%)   |                           |   |   |   |         |
| No                           | 33 (46.5)                 | 32 (45.1) | 33 (46.5) | 30 (42.3) | .075    |
| Yes                          | 38 (53.5)                 | 39 (54.9) | 38 (53.5) | 41 (57.7) |         |
| History of drink, No. (%)   |                           |   |   |   |         |
| No                           | 39 (54.9)                 | 38 (53.5) | 44 (62.0) | 48 (67.6) | .293    |
| Yes                          | 32 (45.1)                 | 33 (46.5) | 27 (38.0) | 23 (32.4) |         |
| Hypertension, No. (%)        |                           |   |   |   |         |
| No                           | 40 (56.3)                 | 48 (67.6) | 49 (69.0) | 46 (64.8) | .293    |
| Yes                          | 31 (43.7)                 | 23 (32.4) | 22 (31.0) | 25 (35.2) |         |
| Hyperlipidemia, No. (%)      |                           |   |   |   | 1.000   |
| No                           | 47 (66.2)                 | 48 (67.6) | 51 (71.8) | 46 (64.8) |         |
| Yes                          | 24 (33.8)                 | 23 (32.4) | 20 (28.2) | 25 (35.2) |         |
| Diabetes, No. (%)            |                           |   |   |   | .941    |
| No                           | 64 (90.1)                 | 55 (77.5) | 59 (83.1) | 63 (88.7) |         |
| Yes                          | 7 (9.9)                   | 16 (22.5) | 12 (16.9) | 8 (11.3)  |         |
| Tumor differentiation, No. (%)|                         |   |   |   | .185    |
| Well                         | 12 (16.9)                 | 12 (16.9) | 14 (19.7) | 15 (21.1) |         |
| Moderate                     | 40 (56.3)                 | 42 (59.2) | 40 (56.4) | 44 (62.0) |         |
| Poor                         | 19 (26.8)                 | 17 (23.9) | 17 (23.9) | 12 (16.9) |         |
| Tumor size, No. (%)          |                           |   |   |   | .097    |
| ≤5.0 cm                      | 36 (50.7)                 | 37 (52.1) | 47 (66.2) | 43 (60.6) |         |
| >5.0 cm                      | 35 (49.3)                 | 34 (47.9) | 24 (33.8) | 28 (39.4) |         |
| Lymph node metastasis, No. (%)|                       |   |   |   | <.001   |
| No                           | 33 (46.5)                 | 50 (70.4) | 54 (76.1) | 53 (74.6) |         |
| Yes                          | 38 (53.5)                 | 21 (29.6) | 17 (23.9) | 18 (25.4) |         |
| TNM stage, No. (%)           |                           |   |   |   | .001    |
| I                            | 15 (21.1)                 | 21 (29.6) | 29 (40.9) | 24 (33.8) |         |
| II                           | 22 (31.0)                 | 24 (33.8) | 26 (36.6) | 31 (43.7) |         |
| III                          | 34 (47.9)                 | 26 (36.6) | 16 (22.5) | 16 (22.5) |         |
| CEA, No. (%)                 |                           |   |   |   | .089    |
| Normal                       | 26 (36.6)                 | 35 (49.3) | 37 (52.1) | 36 (50.7) |         |
| Abnormal                     | 45 (63.4)                 | 36 (50.7) | 34 (47.9) | 35 (49.3) |         |

*Q1: quartile 1, Q2: quartile 2, Q3: quartile 3, Q4: quartile 4. Correlation was determined by linear-by-linear association test or Spearman’s rank correlation test. CEA, carcinoembryonic antigen.
Several previous studies have reported the dysregulation of circ_0001946 in tumor tissues. For instance, it is suggested that circ_0001946 is downregulated in the tumor tissues compared to the non-tumor tissues in esophageal squamous cell cancer patients.\textsuperscript{15} Besides, another study reveals that circ_0001946 is also reduced in the tumor tissues compared to the paired non-cancerous tissues in bladder cancer patients.\textsuperscript{12} However, circ_0001946 relative expression in NSCLC patients is largely unclear. In the present study, we analyzed the 284 NSCLC tumor tissues and 125 adjacent non-tumor tissues, and found that circ_0001946 was downregulated in the tumor tissues compared to the adjacent tissues of NSCLC patients, which was in line with a previous study.\textsuperscript{14} Possible explanations for our data might be that (a) circ_0001946 low expression might activate the NER pathway to directly increase the incidence of NSCLC\textsuperscript{16}; (b) as a competing endogenous circRNA, circ_0001946 low expression might increase several miRNAs that could promote tumorigenesis, such as miR-671-5p\textsuperscript{17} (as in glioblastoma\textsuperscript{11}), thus indirectly promoted the incidence of NSCLC. Therefore, circ_0001946 was reduced in tumor tissues compared to adjacent non-cancerous tissues in NSCLC patients.

Regarding the correlation of circ_0001946 with tumor characteristics, one interesting previous study suggests that circ_0001946 dysregulation is negatively correlated with tumor size, histologic grade, lymphatic metastasis, and TMN stage in colorectal cancer. This suggests a potential role for circ_0001946 in the development and progression of NSCLC, and further study is needed to validate these findings.
patients. In the present study, data showed that higher tumor circ_0001946 expression was associated with less lymph node metastasis and lower TNM stage. Our data could be explained by that (a) higher circ_0001946 might suppress the epithelial-mesenchymal transition to promote the migration and invasion ability of NSCLC cells, thus decreasing its metastatic potential (as in colorectal cancer). Therefore, higher circ_0001946 was correlated with less lymph node metastasis in NSCLC patients; (b) higher circ_0001946 expression might reduce the level of several miRNAs that promote the progression of cancers, such as miR-671-5p (as in glioblastoma), thus suppressing NSCLC cell proliferation, migration, and invasion, and resulting in lower TNM stage.

Identifying potential prognostic biomarkers might improve the management toward NSCLC patients, thus ameliorating their overall prognosis. Meanwhile, the prognostic value of circ_0001946 has been reported by previous studies. For example, circ_0001946 expression was categorized as 0%-25% quartile = 0, 25%-50% quartile = 1, 50%-75% quartile = 2, and 75%-100% quartile = 3.

### TABLE 3 Analysis for factors correlated with DFS

| Items                                      | P value | HR     | 95% CI Lower | 95% CI Higher |
|--------------------------------------------|---------|--------|--------------|---------------|
| Higher circ_0001946 expression             | <.001   | 0.714  | 0.621        | 0.820         |
| Age > 60 y                                 | .033    | 0.714  | 0.523        | 0.973         |
| Hyperlipidemia                             | .020    | 1.487  | 1.066        | 2.075         |
| Lymph node metastasis                      | .004    | 1.711  | 1.189        | 2.462         |
| Higher TNM stage                           | <.001   | 1.620  | 1.268        | 2.072         |
| RT                                         | .016    | 0.601  | 0.397        | 0.910         |

Note: Factors correlated with DFS were analyzed by forward stepwise multivariate Cox’s proportional hazard regression model.

Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; RT, radiotherapy.

FIGURE 5 Subgroup analysis of the association between tumor circ_0001946 expression and OS in NSCLC patients with different TNM stages. (A) Correlation of TNM stage with OS; (B) correlation of tumor circ_0001946 with OS in patients with TNM stage I; (C) correlation of tumor circ_0001946 with OS in patients with TNM stage II; and (D) correlation of tumor circ_0001946 with OS in patients with TNM stage III. Circ_0001946, circular RNA_0001946; NSCLC, non-small-cell lung cancer; OS, overall survival.
dysregulation could be an indicator of worse prognosis in bladder cancer patients and esophageal squamous cell cancer patients. However, the prognostic value of circ_0001946 in NSCLC patients is not clear. In the present study, we found that higher tumor circ_0001946 was correlated with improved DFS and OS in NSCLC patients. Meanwhile, subgroup analysis revealed that higher tumor circ_0001946 was further correlated with improved DFS in NSCLC patients with TNM stage I, II, or III. Third, the long-term prognostic value of circ_0001946 in NSCLC patients was not investigated, which could be conducted further. Fourth, this study was a retrospective study, which might cause selection bias, and further prospective study could be conducted.

To be conclusive, circ_0001946 is reduced in tumor tissues, while its higher expression correlates with reduced lymph node metastasis, decreased TNM stage, and improved prognosis in NSCLC patients.

ORCID
Ke Zhao https://orcid.org/0000-0002-0553-5245

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.
2. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-1640.
3. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299-311.
4. Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9):170070.
5. She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest. 2013;143(4):1117-1126.
6. Lam WK, White NW, Chan-Yeung MM. Lung cancer epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2013;88(9):1045-1057.
7. Di X, Jin X, Li R, et al. CircRNAs and lung cancer: Biomarkers and master regulators. Life Sci. 2019;220:177-185.
8. Hoseok I, Cho JY. Lung cancer biomarkers. Adv Clin Chem. 2015;2015:72:107-170.
9. Salzman J. Circular RNA. Expression: its potential regulation and function. Trends Genet. 2016;32(5):309-316.
10. Qu S, Yang X, Li X, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141-148.
11. Li X, Diao H. Circular RNA circ_0001946 acts as a competing endogenous RNA to inhibit glioblastoma progression by modulating miR-671-5p and CDR1. J Cell Physiol. 2019;234(8):13807-13819.
12. Shen C, Wu Z, Wang Y, et al. Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and...
predict poor prognosis for bladder cancer patients. *Cancer Med.* 2020;9(11):3885-3903.

13. Deng Z, Li X, Wang H, et al. Dysregulation of CircRNA_0001946 contributes to the proliferation and metastasis of colorectal cancer cells by targeting MicroRNA-135a-5p. *Front Genet.* 2020;11:357.

14. Huang MS, Liu JY, Xia XB, et al. Hsa_circ_0001946 inhibits lung cancer progression and mediates cisplatin sensitivity in non-small cell lung cancer via the nucleotide excision repair signaling pathway. *Front Oncol.* 2019;9:508.

15. Fan L, Cao Q, Liu J, et al. Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis. *Mol Cancer.* 2019;18(1):16.

16. Marteijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. *Nat Rev Mol Cell Biol.* 2014;15(7):465-481.

17. Yu Y, Wang Z, Sun D, et al. miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor SOX6. *Eur J Pharmacol.* 2018;823:65-71.

How to cite this article: Zhang M, Wen F, Zhao K. Circular RNA_0001946 is insufficiently expressed in tumor tissues, while its higher expression correlates with less lymph node metastasis, lower TNM stage, and improved prognosis in NSCLC patients. *J Clin Lab Anal.* 2021;35:e23625. [https://doi.org/10.1002/jcla.23625](https://doi.org/10.1002/jcla.23625)